Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07295847 · ClinicalTrials.gov registry record · Phase 1

A Study of AZD0120 in Autoimmune Diseases

A Phase 1 study of Rheumatoid Arthritis and Systemic Sclerosis, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
27
Enrollment target
18
Study locations

NCT07295847: Recruiting Phase 1 study of Rheumatoid Arthritis and Systemic Sclerosis, sponsored by AstraZeneca.

NCT07295847 is a Phase 1 study of Rheumatoid Arthritis and Systemic Sclerosis that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 27 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 18 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07295847, a Phase 1 study of Rheumatoid Arthritis and Systemic Sclerosis, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
27 participants
Enrollment target
18
Study locations

Study Summary

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).

Primary Outcome

Incidence and severity of DLTs and TEAEs to evaluate the safety of AZD0120 and to confirm the recommended Phase 2 dose (RP2D) in each indication SSc, IIM, or RA

Conditions Studied

Rheumatoid Arthritis Systemic Sclerosis Idiopathic Inflammatory Myopathies

Interventions

  • BIOLOGICAL AZD0120

Study Locations (18)

Other

  • Research Site - Darlinghurst
  • Research Site - Waratah
  • Research Site - Hamburg
  • Research Site - Mainz Am Rhein
  • Research Site - Würzburg
  • Research Site - Barcelona
  • Research Site - Madrid
  • Research Site - Madrid
  • Research Site - Edinburgh
  • Research Site - London

Arizona

  • Research Site - Tucson

California

  • Research Site - Stanford

Illinois

  • Research Site - Chicago

Michigan

  • Research Site - Ann Arbor

Missouri

  • Research Site - St Louis

New York

  • Research Site - New York

North Carolina

  • Research Site - Chapel Hill

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2026-01-09
Est. Completion 2028-02-22
Phase Phase 1
AstraZeneca

1,285 total trials

What NCT07295847 shows while recruiting

NCT07295847 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which AZD0120 is the first listed.

NCT07295847 lists 18 locations in 9 states (Other, Arizona, California).

Frequently Asked Questions

What is clinical trial NCT07295847 about?

NCT07295847 is a clinical study titled "A Study of AZD0120 in Autoimmune Diseases". This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthr...

What is the current status of trial NCT07295847?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2026-01-09. Estimated completion is 2028-02-22.

What conditions does trial NCT07295847 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis, Systemic Sclerosis, Idiopathic Inflammatory Myopathies.

What interventions are being tested in trial NCT07295847?

The interventions under investigation include: AZD0120 (BIOLOGICAL).

Who is sponsoring clinical trial NCT07295847?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07295847 being conducted?

This trial has 18 study locations across Arizona, California, Illinois, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07295847's enrollment target sits among peer trials

27 167th of 197 higher than 31 of 197 other Rheumatoid Arthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00912041 · 27 participants · NA

    BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

  • NCT02847559 · 27 participants · Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

  • NCT03380195 · 27 participants · NA

    Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness

  • NCT03384238 · 27 participants · Phase 1

    Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07295847

Source: ClinicalTrials.gov NCT07295847, the US trial registry maintained by the National Library of Medicine. NCT07295847 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.